Publications (41) View all
-
Article: Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
02/2013; 6(2):182-4. · 1.07 Impact Factor -
Article: Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
Journal of Thrombosis and Thrombolysis 08/2012; 34(3):297-9. · 1.48 Impact Factor -
Article: Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
[show abstract] [hide abstract]
ABSTRACT: Antiplatelet therapy is the cornerstone of treatment in preventing ischemic events in patients with coronary artery disease (CAD), particularly in the setting of acute coronary syndromes and percutaneous coronary interventions. However, antiplatelet therapy is also associated with an increased risk of bleeding complications, which are more frequent with the use of more potent antiplatelet treatment regimens. Therefore, defining the balance between the risk of thrombotic events and the risk of bleeding is essential to improve overall clinical outcomes. The pharmcodynamic effects of antiplatelet agents vary broadly and may be associated with differences in outcomes. In particular, patients are at an increased risk of ischemic or bleeding complications if the pharmacodynamic effects are reduced or enhanced, respectively. Multiple platelet function assays are currently available to assess the pharmacodynamic effects of commonly used antiplatelet agents. The present manuscript will review the prognostic value of platelet function testing to identify patients with CAD at risk of bleeding complications and the potential applications of these tests in the modern era of antiplatelet pharmacotherapy.Platelets 07/2012; 23(7):537-51. · 1.85 Impact Factor -
Article: Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
[show abstract] [hide abstract]
ABSTRACT: Platelet activation and aggregation is a complex and key process in thrombus formation after the rupture of an atherosclerotic plaque, which can lead to an acute coronary syndrome. Aspirin, an irreversible inhibitor of thromboxane A(2) synthesis, in combination with an inhibitor of P2Y(12) ADP platelet receptors (clopidogrel, prasugrel or ticagrelor), represents the current standard of care of antiplatelet therapy for patients with acute coronary syndrome and in those patients undergoing percutaneous coronary intervention. Despite the benefit of these agents, the risk of thrombotic events and bleeding complications may still occur while on such antiplatelet treatment regimens, thus representing an important limitation. Thrombin is one of the most important platelet activators. The inhibition of thrombin-mediated platelet activation by means of protease-activated receptor-1 inhibitors represents an attractive therapeutic option for patients with atherothrombotic disease processes. This article provides an overview on atopaxar (E5555), an orally active protease-activated receptor-1 antagonist that has recently completed Phase II clinical investigation.Future Cardiology 07/2012; 8(4):503-11. -
Article: Prasugrel.
[show abstract] [hide abstract]
ABSTRACT: Prasugrel is a third-generation thienopyridine which selectively inhibits the platelet P2Y(12) receptor more rapidly, more potently, and with less interindividual response variability compared with the second-generation thienopyridine clopidogrel. Large-scale phase III clinical testing showed that in high-to moderate-risk acute coronary syndrome patients undergoing percutaneous coronary intervention, prasugrel translates into a greater reduction in ischemic events, including stent thrombosis, in the short and long term compared to clopidogrel. Prasugrel, however, is associated with an increased risk of major bleeding, which is more pronounced in certain patient subgroups. The ideal patient population for prasugrel use are those patients without prior transient ischemic attack/stroke, <75 years of age and >60 kg in whom the greatest ischemic benefit is achieved without a significant increase in major bleeding risk. Dose modifications in specific populations or at given time-points may represent an avenue to minimize bleeding risk and therefore maximize the clinical benefit of prasugrel. Ongoing clinical studies with prasugrel will better define the safety and efficacy profiles of this agent and potentially set the basis for new indications for use.Advances in cardiology 01/2012; 47:39-63.
